OUR COMPANY

We are Seqirus

On the Front Line

Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic and we have been committed to the fight against influenza ever since.

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.

Our vision is a world protected from influenza.

100 Years

As part of the CSL Group, Seqirus draws on over a century of experience in influenza vaccines. From 1916 to today, CSL has been driven by the promise to save lives using the latest technologies.

1916

Commonwealth Serum Laboratories (CSL) is established to service the health needs of an infant Australian nation.

1916

1919

When the deadly Spanish influenza pandemic strikes Australia, CSL responds rapidly with 3 million doses of a mixed bacterial vaccine.

1919

1930

CSL releases a tiger snake antivenom, and goes on to develop antivenoms for Australia’s most venomous creatures.

1930

1942

Production commences on an influenza virus vaccine and the first 1 million doses are supplied to Australian and British troops.

1942

1951

WHO designates CSL as a Influenza Reference Laboratory to enhance Southern Hemisphere influenza surveillance.

1951

1957-8

CSL responds quickly to the Asian influenza pandemic, producing 1.6 million doses of vaccine.

1957

Flu production or Hong King flu vaccine poster

1968-9

As the Hong Kong influenza pandemic emerges, CSL produces 5 million doses of vaccine to protect the region.

1968

1992

WHO designates CSL as an Influenza Collaborating Centre, strengthening its role in the global influenza network.

1992

1994

CSL becomes a private company.

1994

2002

CSL extends its influenza vaccine supply into the Northern Hemisphere.

2002

2009

The organisation's rapid response to the H1N1 (swine flu) pandemic sees Australia become one of the first countries in the world to roll-out vaccine to its population, with stocks also donated to the WHO.

2009

2015

Seqirus, one of the largest influenza vaccine manufacturers in the world, is created when CSL acquires the Novartis' influenza vaccine business, combining it with bioCSL.

2015

2016

Seqirus launches three new products and is well positioned for the future.

2016

Holly Springs Manufacturing - image library

2018

Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process.

2018

Global Presence

Seqirus has manufacturing and R&D hubs across three continents, a globally integrated supply chain and a commercial presence in more than 20 countries.

See our Global Presence Map

Corporate Responsibility

At Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities. We believe that behaving responsibly is critical to the sustainability of our company.

Learn more

In the Community

Helping people and communities by lending our expertise, supporting education and improving access to influenza vaccines and life-saving products, is part of our Corporate Responsibility.

Learn more

Our Leadership

The Seqirus Leadership Team has deep expertise in the business of influenza and a shared commitment to public health.

Learn more

Our Values

Our Values are fundamental to our success — helping us to save lives, protect the health of people, and earn our reputation as a trusted and reliable global leader. They are at the core of how people at Seqirus interact with others, make decisions and solve problems.